Docoh
Loading...

QGEN Qiagen

News

From Benzinga Pro
QIAGEN Launches QIAwave Portfolio Of Environmentally Friendly Products
18 Jan 22
News
QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)))) today announced its new QIAwave product line by launching three nucleic acid extraction kits that use fewer components and produce less waste than existing ones.
What Does Qiagen's Debt Look Like?
13 Jan 22
News, Intraday Update, Markets
Over the past three months, shares of Qiagen (NYSE:QGEN) moved lower by 5.06%. Before we understand the importance of debt, let us look at how much debt Qiagen has.
QIAGEN Says Co's Liquid-Based Sample-Prep-And-Detection Kit Helps Labs Ramp Up COVID Testing
13 Jan 22
News
https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2022/QIAGENs-liquid-based-sample-prep-and-detection-kit-helps-labs-ramp-up-COVID-testing-capacity-by-slashing-processing-times/default.as
'FDA Acting Commissioner Woodcock on rapid tests. There are now total of 15 authorized by FDA. New program in place to accelerate review of these tests.' -News Nation Reporter
11 Jan 22
News, FDA
https://twitter.com/EvanLambertTV/status/1480927544518094860
QIAGEN Says Expands QIAstat-Dx Syndromic Testing Menu, Announces Launch Plans For QIAstat-Dx Rise Higher-Throughput Version
10 Jan 22
News, FDA
QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)))) today announced important enhancements in the commercialization of its QIAstat-Dx syndromic testing solution – which enables laboratories and hospitals
QIAGEN Announced New Collaborations to Extend the QIAcuity Ecosystem
7 Jan 22
News
QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced new additions to the growing number of applications for QIAcuity, its ultrasensitive digital PCR (dPCR) platform that has set new standards by using so-called nanoplates to process samples in two hours rather than the five hours required by other systems.
FDA Website Shows Dec. 22-Dated update On Antigen Tests For Omicron: 'The FDA continues to monitor and evaluate the impact of genetic variants on antigen tests...'
22 Dec 21
Biotech, News, Rumors, FDA, General
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests?utm_medium=email&utm_source=govdelivery#omicronvariantimpact
President Biden Tweets 'Starting this week, the federal government will set up emergency testing sites in areas that need additional testing capacity. Before Christmas, the first several of these federal testing sites will be up and running in New York..'
21 Dec 21
News, Politics, FDA, General
https://twitter.com/POTUS/status/1473402686955479041
New York Attorney General Issues Post 'Attorney General James Issues Warning to LabQ Diagnostics to Stop Misrepresenting Turnaround Times for COVID-19 Test Results'
21 Dec 21
News, FDA
https://ag.ny.gov/press-release/2021/attorney-general-james-issues-warning-labq-diagnostics-stop-misrepresenting
Wells Fargo Maintains Equal-Weight on Qiagen, Raises Price Target to $60
14 Dec 21
News, Price Target, Analyst Ratings
Wells Fargo analyst Dan Leonard maintains Qiagen (NYSE:QGEN) with a Equal-Weight and raises the price target from $58 to $60.
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
9 Dec 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
'Senate votes to repeal key Biden administration vaccine and testing policy' -Earlier Washington Post Report
8 Dec 21
News, Politics, Hot, General
https://www.washingtonpost.com/us-policy/2021/12/08/republicans-vaccine-congress-coronavirus/
White House Chief Of Staff Ronald Klain Says President Biden Will Announce Today 'FREE and RELIABLE' COVID At Home Tests
2 Dec 21
News, Politics, FDA, General
https://twitter.com/WHCOS/status/1466404937525567496?s=20
'Stricter coronavirus testing to be required for all travelers to the U.S. amid omicron variant concerns' -Washington Post Report
30 Nov 21
News
https://www.washingtonpost.com/health/2021/11/30/omicron-stricter-travel-rules-us-entry/
Qiagen Says Its COVID-19 PCR Tests Can Detect The New South African Variant
26 Nov 21
Long Ideas, News, Health Care, Movers, Trading Ideas, General
Qiagen N.V. (NYSE: QGEN) announced that its polymerase chain reaction (PCR)
QIAGEN Reaffirms Effectiveness Of Its SARS-CoV-2 PCR Tests In Light Of New Coronavirus Variant B.1.1.529
26 Nov 21
News
QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)))) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the emergence of a new
Qiagen, Becton Dickinson Settle Patent Infringement Lawsuit For $53M
8 Nov 21
News, Health Care, Legal, Movers, Trading Ideas, General
Qiagen Clocks 17% Increase In Non-COVID Product Sales; Raises FY21 Guidance
4 Nov 21
Earnings, News, Guidance, Health Care, General
Qiagen Q3 EPS $0.58 Beats $0.47 Estimate, Sales $535.00M Beat $434.97M Estimate
3 Nov 21
Earnings, News
Qiagen (NYSE:QGEN) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.47 by 23.4 percent. This is unchanged from the same period last year. The company reported quarterly
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
3 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap
Here's a roundup of top developments in the biotech space over the last 24 hours.

Press releases

From Benzinga Pro
QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021
19 Jan 22
Press Releases
QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the fourth quarter and full-year results of 2021 on Tuesday, February 8, at approximately 16:05
QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products
18 Jan 22
Press Releases
New extraction kits reduce use of plastics by up to 63% and cardboard by up to 42% compared to QIAGEN standard kits Three offerings are first of a wave of sustainability-driven product innovations Company reduces
QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version
10 Jan 22
Press Releases
New tests for QIAstat-Dx syndromic solution to distinguish between gastrointestinal pathogens (U.S. submission) and between meningitis and encephalitis infections (CE-IVD registration) Higher-capacity QIAstat-Dx
QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations
7 Jan 22
Press Releases
Expanding range of applications for growing base of QIAcuity digital PCR instruments Two new collaborations: Atila BioSystems expands menu to non-invasive prenatal testing (NIPT), while Actome partnership designed to
QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB
6 Jan 22
Press Releases
QuantiFERON franchise benefits from new applications, products and automation options, building on strengths in tuberculosis detection while addressing new disease targets QuantiFERON SARS-CoV-2 assay launched in
Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
9 Dec 21
Press Releases
SAN DIEGO and GERMANTOWN, Md. and HILDEN, Germany, Dec. 9, 2021 /PRNewswire/ -- Denovo Biopharma LLC and QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced a collaboration to develop a blood-based
QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
9 Dec 21
Press Releases
QIAGEN's blood-based test will help to identify patients with Diffuse Large B-Cell Lymphoma (DLBCL) likely to respond to Denovo's new investigational cancer treatment DB102TM The partners seek FDA premarket approval
QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19
2 Dec 21
Press Releases
Easy-to-use workflow can detect T-cell response early in the course of COVID-19 infection or following vaccination Detection of T-cells can provide vital insights that completes the picture of SARS-CoV-2 immune
QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS
29 Nov 21
Press Releases
Additional U.S. approval for LIAISON® XS platform builds on FDA approval in 2019 for QuantiFERON assay running on DiaSorin's LIAISON® XL analyzer Collaboration now provides full range of automation
QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavirus variant B.1.1.529
26 Nov 21
Press Releases
QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the emergence of a new
Thinking about trading options or stock in Qiagen NV, NetEase, Boeing, Hollysys Automation Technologies, or Walmart?
16 Nov 21
Opinion, Press Releases
NEW YORK, Nov. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QGEN, NTES, BA, HOLI, and WMT.
Companion Diagnostics Market size worth $ 10 Billion, Globally, by 2028 at 13% CAGR: Verified Market Research®
11 Nov 21
Press Releases
JERSEY CITY, N.J., Nov. 11, 2021 /PRNewswire/ -- Verified Market Research recently published a report, "Companion Diagnostics Market" By Technology Type (Frequency Immunohistochemistry, Polymerase Chain Reaction
Actym Therapeutics Appoints Chan Whiting as Chief Development Officer
11 Nov 21
Press Releases
BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience
QIAGEN Commits to Reduce Carbon Emissions by Setting Science-Based Target to Reach Net Zero by 2050
8 Nov 21
Press Releases
Joins "Business Ambition for 1.5˚C" campaign of the Science-Based Targets initiative Commitment to achieve by 2030 at least 40% reduction in Scope 1 and 2 emissions, and at least 10% reduction in Scope 3 emissions,
QIAGEN and BD Settle Patent Infringement Lawsuit
5 Nov 21
Press Releases
QIAGEN N.V. (NYSE:QGEN, Frankfurt Stock Exchange: QIA)) and BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that they have reached a settlement in the patent infringement lawsuit related to QIAGEN's
QIAGEN Reports Strong Results for Third Quarter and First Nine Months Of 2021
3 Nov 21
Press Releases
Q3 2021: Net sales rise 11% (+10% constant exchange rates, CER) to $535 million and adjusted diluted EPS unchanged at $0.58 ($0.58 CER) from Q3 2020, both well above outlook Non-COVID product group sales grow 17% CER
QIAGEN expands QIAstat-Dx testing menu with respiratory four-plex panel that differentiates between flu, RSV and SARS-CoV-2
2 Nov 21
Press Releases
Easy-to-use cartridge receives CE-marking in Europe and will launch soon Syndromic test differentiates between influenza A and B, RSV and SARS-CoV-2, a critical test for upcoming flu seasons Test broadens QIAGEN's